Table of Contents
CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - France
Pharmaceuticals market in France is set to decline from $35.5 billion in 2017 to $34.16 billion in 2021, representing a negative compound annual growth rate of 1%.
Despite France’s robust public health insurance system and rising elderly population, increasing pressure on pharmaceutical selling prices, patent expiration of branded drugs and foreign exchange fluctuations are stifling growth. The government is currently focusing on the use of generics as a cost-containment tool to reduce healthcare expenditure. Indeed, the generics market is mainly driven by a favorable regulatory regime and a continuous wave of patent expiries, acting as a barrier to pharmaceutical market growth.
France follows external reference pricing, which is linked with other European countries such as Germany, Spain, Italy, and the UK. A price cut by any of these countries’ governments will quickly translate into price reductions in France, and repeated price cuts have curtailed the rise in healthcare spending.
France’s reimbursement policy is grounded in clinical effectiveness rather than the cost-versus-benefit approach that other countries such as the US and the UK employ. This means that pharmaceutical companies take a higher risk in order to see returns on innovative products, and new drugs have to demonstrate a level of improvement over existing products, which can be seen as a deterrent to investment.
Healthcare companies looking for opportunities within the French market should focus on the growing demand for innovative medicine and biotechnology, which will enable new therapies to command a premium price and influence the value of the market. Financial incentives and tax credits from the French government to support pharmaceutical R&D will promote new prospects for small biotechnology companies, a growing number of which have been operating in France over the past decade.
The report provides information on the healthcare, regulatory, and reimbursement landscape in France, and includes -
- An overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers
- Profiles and SWOT analyses of the major players in the pharmaceutical market: Novartis, Sanofi, Pfizer, Merck & Co. and Mylan; and profiles and SWOT analyses of the major players in the medical device market: B. Braun Melsungen, Medtronic, Roche, Johnson & Johnson and GlaxoSmithKline (GSK)
- An insightful review of the reimbursement and regulatory landscape, with analysis covering details of the country’s healthcare reimbursement process, regulatory agencies and the approval processes for new drugs and medical devices
- Detailed analysis of the country’s political and economic environment, covering economic indicators, demographics, healthcare infrastructure and healthcare expenditure
- An overview of the opportunities for and challenges to growth in the French healthcare market
Reasons to buy
This report will enhance your decision-making capability by allowing you to -
- Develop business strategies by understanding the trends shaping and driving French healthcare market
- Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments and companies likely to impact France’s healthcare market in the future
- Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing competitors’ performance
- Organize your sales and marketing efforts by identifying the market categories and segments that present the most opportunities for consolidation, investment and strategic partnership
Get Industry Insights. Simply.
Talk to Veronica
+1 718 514 2762
The global healthcare IT market is expected to grow at a CAGR of 15.9% from 2016 to 2021 and reach USD 280.25 billion. Growing need to manage regulatory compliance through healthcare IT solutions, government ...
Digital transformation helps enterprises improve operational performance, efficiency, and business process. It involves the utilization of digital technologies, such as mobility, analytics, and social ...
The ultrasound market is expected to reach USD 6.86 billion by 2021 at a CAGR of 5.2% during 2016-2021. North America and Europe held the largest share of the market in 2016; however, the Asia-Pacific ...